The Pattern of Use, Effectiveness, and Safety of Gadoteric Acid (Clariscan) in Patients Undergoing Contrast-Enhanced Magnetic Resonance Imaging: A Prospective, Multicenter, Observational Study

Table 1

Demographics and clinical characteristics of patients in the whole study population.

Category	N = 1376
	N (%)
Gender
Male	651 (47.3)
Female	725 (52.7)
Age (years), mean ± SD	52.6 ± 25.2
Height (cm), mean ± SD	153.5 ± 27.0
Weight (kg), mean ± SD	57.5 ± 21.0
BMI (kg/m^2), mean ± SD	22.9 ± 4.0
Referral
Routine	1323 (96.2)
Emergency	53 (3.9)
Follow-up	0 (0.0)
MR examination	N (%)
Volume use (mL/kg), mean ± SD (median, min, max)	0.26 ± 0.09 (0.21, 0.08, 0.51)
Automatic injector used
Yes	948 (68.9)
No	428 (31.1)
Field strength of MRI
1.5 T	77 (5.6)
3 T	1299 (94.4)
Other	0 (0.0)
Previous imaging examinations^∗
MRI	806 (58.6)
CT	445 (32.3)
Ultrasound	273 (19.8)
PET	94 (6.8)
SPECT	31 (2.3)
None	288 (20.9)
Medical history	N (%)
Allergies
Yes	40 (2.9)
No	1336 (97.1)
On renal replacement
Yes	4 (0.3)
No	1372 (99.7)
Concomitant medications^∗
Beta-blocker	41 (3.0)
Vasoactive substances	13 (0.9)
ACE inhibitors	6 (0.4)
Angiotensin receptor antagonist	58 (4.2)
None	1282 (93.2)
Comorbidities	N (%)
No	996 (72.4)
Yes	380 (27.6)
Types of comorbidities
Hypertension	186 (13.5)
DM	119 (8.7)
CNS disorder (seizures/epileptics/convulsion)	40 (2.9)
Heart failure	22 (1.6)
History of kidney disease	15 (1.1)
History of CM ADR	13 (0.9)
Liver disease/liver transplantation/liver surgery	13 (0.9)
Allergic disorder	4 (0.3)
Asthma	3 (0.2)
History of kidney surgery	2 (0.2)
Others	134 (9.7)

Multiple responses.